Sugi Predict

Sugi Predict / Compounds / SCHEMBL24764220

SCHEMBL24764220

SCHEMBL24764220

CC(C)NCCOCCOCCOCC(=O)C(C)S

nearest known ligand 0.42

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.42
▸ POLB P06746 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22374671 0.93 KDM4E (0.38) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL21026077 0.90 MEN1 (0.35) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL21105824 0.86 KDM4E (0.43) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL11956477 0.86 KDM4E (0.43) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL861505 0.86 KDM4E (0.43) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL21898996 0.84 MEN1 (0.42) KDM4ETDP1MEN1KMT2A
SCHEMBL20325067 0.83 KDM4E (0.38) KDM4ETDP1MEN1KMT2ACYP1A2
SCHEMBL23695750 0.82 KDM4E (0.43) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL21107498 0.82 KDM4E (0.43) KDM4EPOLBTDP1MEN1KMT2A
SCHEMBL16543781 0.82 KDM4E (0.40) KDM4EPOLBTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 — — US disclosed
US-11679109-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-06-20 — — US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 — — US disclosed
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 KDM4E 541/4885POLB 1179/4885TDP1 3132/4885
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885POLB 2088/4885TDP1 236/4885
US-20240024318-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCA2, SMARCC2 KDM4E 223/4885POLB 22/4885TDP1 151/4885
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885POLB 2088/4885TDP1 236/4885
US-11679109-B2 SMARCA degraders and uses thereof SMARCA1, SMARCA2, SMARCC2 KDM4E 223/4885POLB 22/4885TDP1 151/4885
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF MERTK, ITK, CRKL KDM4E 542/4885POLB 1911/4885TDP1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.